Hirudoid (Chondroitin Polysulfate)

Hirudoid 0.5 % w/w cream is applied to the skin to support the natural resolution of minor bruising, swelling, and superficial vascular inflammation that result from everyday injuries or minor circulatory disturbances.

• Bruising (contusions) – helps reduce the visible discoloration and discomfort associated with blunt‑force injuries.
• Superficial thrombophlebitis – applied to the affected vein to lessen localized inflammation and clot formation.
• Hematoma – used on small collections of blood under the skin to promote gradual reabsorption.
• Post‑traumatic swelling – assists in limiting edema after sprains, strains, or minor surgical procedures.
• Dermatologic inflammation – may be used on mild irritant dermatitis or localized skin redness.

• Chondroitin polysulfate exerts its activity by inhibiting key steps in the coagulation cascade, specifically reducing thrombin and factor Xa activity, which limits fibrin formation at the site of application. In parallel, it modulates inflammatory pathways by decreasing leukocyte migration and stabilising endothelial membranes, thereby reducing edema and local inflammatory mediator release. These combined anticoagulant and anti‑inflammatory actions help to control the early phases of bruising and swelling without systemic absorption.

Topical application of Hirudoid may be associated with local skin reactions, most of which are mild and reversible.

Common

• Mild itching or pruritus at the application site, typically transient and resolving without treatment.
• Slight burning or stinging sensation that diminishes after a few minutes.
• Localized redness (erythema) of the skin, often fading within 24 hours.
• Dryness or mild peeling of the treated area, indicating mild irritation.

Serious

• Contact dermatitis characterized by redness, swelling, and vesicle formation that may require medical attention.
• Severe allergic reaction such as urticaria or angioedema, presenting with widespread hives or swelling.
• Persistent ulceration or necrosis of the skin at the site of application, indicating tissue damage.
• Systemic hypersensitivity reactions, although rare, that can involve respiratory or cardiovascular symptoms.

When using Hirudoid, certain precautions help minimize the risk of irritation and ensure safe application.

• Apply only to intact, unbroken skin; avoid open wounds or mucous membranes.
• Do not use on infected, inflamed, or ulcerated areas without medical advice.
• Keep the product away from eyes, ears, and the oral cavity.
• Discontinue use and seek professional guidance if a rash or severe irritation develops.
• Avoid prolonged exposure to sunlight or heat on treated skin.
• Use with caution in pregnant or breastfeeding individuals, as safety data are limited.
• Store at room temperature, protected from moisture and direct light.

Topical chondroitin polysulfate has limited systemic absorption, but certain substances may affect its safety or efficacy when used concurrently.

Avoid

• Concurrent use of other topical anticoagulants or strong anti‑inflammatory agents on the same area, which could increase bleeding risk.
• Application over large surface areas combined with systemic anticoagulant therapy, as cumulative anticoagulant effect may be enhanced.

Use with caution

• Use with other skin‑irritating products (e.g., retinoids, benzoyl peroxide) as they may heighten local irritation.
• Combining with systemic corticosteroids or immunosuppressants; monitor for altered wound healing.
• Use in patients receiving chemotherapy agents that affect platelet function; observe for excessive bruising.